Top Markets
#1 Nesa Nesa +816.77%
#2 Cortex Cortex +68.49%
#3 Merlin's Seal BTC Merlin's Seal BTC +45.50%
#4 QuantixAI QuantixAI +23.90%
#5 EXOD EXOD +22.78%
#6 BSquared Network BSquared Network +19.70%
#7 Pons Pons +18.22%
#8 Instadapp Instadapp +16.92%
#9 Magma Finance Magma Finance +12.52%
#10 OpenEden OpenEden +11.84%
Coin of the day
Nesa Nesa
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Surrozen, Inc. Surrozen, Inc.

Surrozen, Inc.

SRZN
Rangering i aksjer #19466
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates... Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6 for the treatment of DME/wet AMD/uveitic macular edema; SZN-113 to treat Fuchs’ endothelial corneal dystrophy and geographic atrophy; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
Aksjekurs
$21.57
Sist synkronisert: 2026-07-31
Markedsverdi
$161.29M
Endring (1 dag)
3.55%
Endring (1 år)
94.32%
Land
US
Handel Surrozen, Inc. (SRZN)

Kategori

Healthcare
EPS for Surrozen, Inc. (SRZN)
EPS per 2026 TTM: 0
Ifølge de siste økonomiske rapportene og aksjekursen til Surrozen, Inc. er selskapets nåværende EPS (TTM) 0. Ved slutten av 2026 hadde selskapet en EPS på 0, lik EPS-en i 2026 som var 0.
EPS-historikk for Surrozen, Inc. fra 2026 til 2026
EPS ved slutten av hvert år
År EPS Endre
Ikke nok data for de angitte datoene.
EPS for lignende selskaper eller konkurrenter
Selskap EPS EPS-forskjell Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $17.32 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $27.74 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $-7.98 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $-5.29 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH